Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects. Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.
Researchers are conducting a study to understand how a medicine called BP1.4979 behaves in the body of healthy volunteers. The study has two main parts. In the first part, we're comparing how the body handles the medicine when given as a slow-release tablet versus a quick-release tablet, both with and without food. This helps us see how different tablet types and meals affect the medicine's journey through the body. The second part involves taking the slow-release medicine twice a day for two weeks, allowing us to learn more about how it works over a longer period. This information is important for potentially treating conditions like binge eating disorder in the future. The study is open to adults of all genders.
At a glance
What is this study about?
This study is all about understanding a potential new medicine called BP1.4979. Think of it like a detective trying to figure out a new car. We want to know how quickly it starts, how efficiently it runs, and how long it stays on the road. In this case, "the car" is the medicine and "the road" is your body.
Specifically, researchers are looking at how your body handles BP1.4979 in two main ways. First, they want to compare a "slow-release" version of the medicine (where it dissolves gradually over time) with a "quick-release" version (where it dissolves much faster). They'll also check if taking the medicine with or without food changes how your body uses it. This is really important because it helps scientists work out the best way for people to take the medicine if it becomes available in the future.
The second part of the study looks at what happens when healthy volunteers take the slow-release version of BP1.4979 for a longer period – twice a day for 14 days. This helps researchers understand how the medicine works in your body when taken regularly over some time. All this information helps scientists learn how to use BP1.4979 most effectively, especially for conditions like binge eating disorder.
Key takeaways
- This study is looking at how a new medicine, BP1.4979, works in your body.
- It compares quick-release and slow-release versions, and how food affects it.
- You would be a healthy adult volunteer (18+ years old).
- It helps scientists understand the medicine better for potential future use in conditions like binge eating disorder.
- You'll have regular medical checks and provide blood samples.
Who may be eligible?
To be part of this study, you need to be an adult, aged 18 or older. The study is open to both men and women.
Because this is an early-stage study to understand how the medicine works in healthy people, specific health conditions or medications you might be taking could mean you are not suitable. The study team will review your health information in detail to make sure it's safe for you to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally healthy?
- Are you comfortable visiting a clinic for multiple appointments?
- Are you willing to provide blood samples as part of the study?
- Are you able to follow specific instructions about taking medication?
What does participation involve?
If you decide to take part, you'll be giving doctors important information about a new medicine. You would likely need to make several visits to a special clinic. During these visits, the study team would:
* **Assessments:** Check your general health, which could include blood tests, measuring your heart rate and blood pressure, and asking about your medical history. * **Medication:** You would be given doses of the study medicine, BP1.4979, either as a slow-release or quick-release tablet, and sometimes with or without food, depending on which part of the study you are in. * **Monitoring:** After you take the medicine, the doctors will regularly take blood samples to see how the medicine levels change in your body over time. * **Follow-up:** There will be regular check-ups to monitor your well-being.
The total duration of your involvement could vary, but you would be fully informed of the time commitment before you agree to take part.
Potential risks and benefits
Locations (1)
- —UnverifiedBelgium
Common questions
What is 'pharmacokinetics' in simple terms?
It's a big word that just means how your body handles a medicine: how it gets into your system, where it goes, what it does, and how your body gets rid of it.
Why are you testing this in healthy people first?
It's important to understand how the drug works and is processed by the body in healthy individuals before it's given to people who are unwell. This helps ensure safety and informs future studies.
What's the difference between 'sustained release' and 'immediate release'?
A 'sustained release' tablet lets the medicine out slowly over hours, while an 'immediate release' tablet releases it all at once, much faster.
Will I know which type of tablet I'm taking?
Yes, this is an 'open-label' study, which means both you and the research team will usually know which type of medicine you are receiving.
What does 'b.i.d.' mean?
It's a medical abbreviation meaning 'twice a day'. So, taking the medicine b.i.d. means you'd take it once in the morning and once in the evening.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.